Thomas Pritzker to Step Down as Hyatt Executive Chairman After Epstein Ties Acknowledged 
Yotta to Build $2 Billion AI Data Centre Hub in India with Nvidia Blackwell Ultra Chips 
Starboard Value Targets Tripadvisor Board Overhaul Amid Stock Slump 
Medical Groups Sue FTC Over Gender-Affirming Care Investigations Amid Trump Policy Dispute 
Waymo Clarifies Role of Remote Workers Amid U.S. Robotaxi Safety Scrutiny 
BHP Group Half-Year Profit Surges as Copper Overtakes Iron Ore on AI-Driven Demand 
Ireland’s Data Protection Commission Launches GDPR Investigation Into X’s AI Chatbot Grok 
OpenAI Nears $100 Billion Funding Round at $850 Billion Valuation: Bloomberg Report 
Vietnam Airlines, Vietjet, and Sun PhuQuoc Airways Sign Major Boeing Aircraft Deals Amid U.S.–Vietnam Trade Talks 
Mark Zuckerberg Testifies in Youth Social Media Addiction Trial Over Instagram Policies 
Qualcomm to Invest $150 Million in India AI Startups, Strengthening Presence in Growing Market 
European IT Hardware Stocks to Watch as Gaming Demand Outpaces Smartphones, Says BofA 
Goldman Sachs Reportedly Drops Diversity Criteria From Board Candidate Evaluations 
Bill Gates Pulls Out of India’s AI Impact Summit Amid Controversy and Event Mismanagement 
Microsoft Responds to ICE Surveillance Concerns Amid Azure Cloud Expansion 
Microsoft Plans $50 Billion AI Investment to Accelerate Growth in the Global South 
Airbus Cuts Jet Production Target Amid Pratt & Whitney Engine Shortages, Q4 Profit Jumps 17% 
 and Lead Plaintiff Deadline - May 28, 2018 - EconoTimes)
NEW YORK, May 02, 2018 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Solid Biosciences Inc. ("Solid" or the "Company") (NASADAQ:SLDB) and certain of its officers, on behalf of shareholders who purchased Solid securities (1) in Solid’s initial public offering on or about January 25, 2018; or (2) on the open market from January 25, 2018 through March 14, 2018, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/sldb.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.
The complaint alleges that throughout the Class Period, defendants made materially false and misleading statements and/or failed to disclose that: (1) Solid’s lead drug candidate, SGT-001, had a high likelihood of causing adverse events in patients; (2) The company misled investors regarding the toxicity of SGT-001; and (3) consequently, defendants’ statements in the Registration Statement regarding Solid Biosciences’ business, operations, and prospects were materially false and/or misleading.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/sldb or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Solid you have until May 28, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]
